Duff & Phelps Advised Comprehensive Clinical Development on the Sale of its Late Phase Division to Clinical Research Advantage, Inc.
In July 2013, Comprehensive Clinical Development (CCD) sold its Late Phase Division to Clinical Research Advantage, Inc., (CRA) a portfolio company of private equity firm, Kinderhook Industries, LLC.
About Comprehensive Clinical Development
Comprehensive Clinical Development is a clinical research company focusing on clinical pharmacology, central nervous system (CNS) and oncology trials. CCD’s Late Phase Division is an industry leader in conducting psychiatric clinical trials, specifically in the areas of Schizophrenia, Bipolar Disorder, Depression, and Alzheimer's Disease, and operates four independent sites in Atlanta (GA), Cerritos (CA), Holliswood (NY) and Washington, D.C.
About Clinical Research Advantage, Inc.
Based in Tempe, Arizona, CRA is a leading trial management organization that provides Phase II - IV clinical trials management services to the pharmaceutical and biotechnology industries. CRA matches pharmaceutical, biotechnology and contract research organizations with its partner medical practices to recruit patients and conduct clinical trials. CRA has provided research services to the pharmaceutical and medical device industries since 1990, and has successfully completed over 10,800 clinical trials.
Duff & Phelps acted as the exclusive financial advisor to CCD in connection with CCD’s §363 sale process pursuant to the U.S. Bankruptcy Code and provided M&A advisory services in connection with the sale of CCD’s Late Phase Division to CRA.